LILLY TRANSDERMAL XANOMELINE TO ENTER PHASE II FOR ALZHEIMER's AFTER ORAL FORMULATION DROPPED; NK-1 ANTAGONIST NEARING CLINICALS FOR CHRONIC PAIN
Executive Summary
Lilly is testing a transdermal patch formulation of its Alzheimer's disease therapy xanomeline to see if the new formulation has a more favorable profile than oral xanomeline, Lilly Research Labs President August Watanabe, MD, told the Oppenheimer & Co. health care conference Nov. 10 in New York City.